Success Stories: Transforming Neurodegeneration Research: EB1A Approval for Leading Scientist in neurodegeneration Studies
Client’s Testimonial:
“It was a pleasure working with Chen on my EB-1A case, and I am incredibly grateful for their dedicated support throughout my EB-1A petition. Their team was professional, thorough, and highly responsive from the first day. They ensured that my petition accurately reflected my work and achievements, which made a significant difference. Thanks to their hard work and attention to detail, my EB-1A petition was approved without any RFE. I highly recommend their services to anyone seeking assistance with their immigration needs.”
On June 21st, 2025, we received another EB1A (Alien of Extraordinary Ability) approval for a Research Associate in the Field of Neurodegeneration (Approval Notice).
General Field: Neurodegeneration
Position at the Time of Case Filing: Research Associate
Country of Origin: India
State of Residence at the Time of Filing: Maryland
Approval Notice Date: June 21st, 2025
Processing Time: 16 days (Premium Processing Requested)
Case Summary:
In the search for answers to some of the most devastating neurological diseases, a dedicated research associate from India is helping redefine what’s possible. With a focus on neurodegenerative disorders, this accomplished scientist has recently secured EB1A (Alien of Extraordinary Ability) approval—a testament to her groundbreaking research and sustained influence in her field.
Her work centers on uncovering cellular dysfunction in neurodegeneration and factors contributing to neurodegenerative disease progression. Her research portfolio includes 10 peer-reviewed journal articles and a book chapter, with work published in some of the field’s most prestigious venues, such as Science Translational Medicine, etc. Her work has been cited over 200 times by peers across 29 countries, a clear indication of its international impact.
Notably, her extensive studies have been implemented by top researchers worldwide. Scholars from institutions such as Stanford, Oxford, the University of Calgary, and the Weizmann Institute have referenced her findings to guide their own investigations into neurodegenerative disorders and neuroprotective therapies.
Beyond authorship, her reputation as a thought leader is evident in her peer review contributions—she has reviewed for more than 36 scholarly journals and serves on the editorial board of a prestigious journal. Her research has also been supported by major funding agencies, including the U.S. Department of Defense’s Multiple Sclerosis Research Program and the Indian Council of Medical Research.
One senior professor summarized her contribution best:
“[Client’s] projects have progressed our understanding of the mechanisms behind ALS and contributed valuable data for the development of ALS therapies. Her expertise is invaluable to advancing our understanding of ALS in the U.S. and worldwide.”
With this EB1A approval, she is now poised to continue her research in the United States, working to decode the molecular underpinnings of neurodegenerative diseases and translate them into real-world treatments. Her focus includes studying key pathways of immune responses in neuroinflammatory and neurodegenerative conditions. At NAILG, we are honored to have supported her journey through the EB1A process. Her story represents not only an extraordinary scientific achievement but also the promise of a better future for patients living with neurodegenerative diseases.